HERE IT IS! 👇 Postdoc on FEP for drug design with us IIT in collab with IAMA Therapeutics Here is the call: iit.taleo.net/careersection/… An excellent opportunity to have an impact and make drugs! Come working with us! Please apply if interested, or RT !

Building a better drug spectrumnews.org/features/deep-… via Spectrum (Autism Research News)

.IAMA Therapeutics is hoping a new class of molecule will prove successful against an old target in autism. By Sama Yhia. Marco De Vivo Andrea P Malizia Luigi Mazzone #neurotwitter #autismresearch bit.ly/3ryyI76

“Our compound so far is much more selective against NKCC1 in the central nervous system,” says Andrea Malizia, Iama’s chief executive officer. By Sama Yhia. Marco De Vivo Andrea P Malizia Luigi Mazzone #autismresearch bit.ly/3RHQejR

If you are interested in, or somehow touched by, autism in the family… or other neuro-developmental disorders in kids … please read this. A critical assessment of what’s going on regarding future medicines. IAMA Therapeutics IIT #autism #epilepsy #drug #Discovery

Marco Borgogno of IAMA Therapeutics presents the Iama SBDD neuroscience drug discovery pipeline #SBDD23

IAMA Therapeutics CEO Andrea P Malizia will be presenting at BioCentury's #BioEquity Europe 2023 in Dublin during the Neurology, Neurodegeneration and Autoimmunity Sessions today, Monday 15th May. Learn more: bit.ly/3IbwnaQ #biotech #lifescience #neuroscience

IAMA Therapeutics CEO Andrea P Malizia will present at the #BIO2023 International Convention in Boston on June 7 at 10:45 AM ET. Read more: bit.ly/3qpIniS #StandUpForScience #Biotech #Neuroscience #Epilepsy #Neurodevelopment #Investment #Partnering #Dealmaking

#ICYMI IAMA Therapeutics announced the key additions of Paul Frohna M.D., Ph.D., PharmD, Pierandrea Muglia, M.D. and Elaine Wirrell, M.D., to its distinguished Scientific Advisory Board. Read more: bwnews.pr/3qvzW5X #Biotech #LifeScience #Neuroscience

IAMA Therapeutics announced a sponsored research agreement with the Sapienza University of Rome, bringing us closer to our goal of making a meaningful impact on children affected by rare neurological disorders. Read more: bit.ly/3PRm2Ws #Biotech #Neurodevelopment

IAMA Therapeutics CEO Andrea P Malizia will present at Sachs Associates 23rd Annual Biotech in Europe Forum in Basel, Switzerland on September 20. Read more: bit.ly/3ZfUjRH #Sachs_BEF #Biotech #LifeScience #Neuroscience #Epilepsy #Neurodevelopment

IAMA Therapeutics announced it has signed a multi-phase agreement with Evotec for preclinical and clinical support in the anticipated Phase 1 study for IAMA-6. Read more: bit.ly/3Q09QlG #Biotech #LifeScience #Neuroscience #Neurodevelopment #Epilepsy #Autism #RareDisease

Today we honor #WorldMentalHealthDay. At IAMA, we are dedicated to unlocking major breakthroughs in neuroscience to develop personalized treatments for patients suffering from untreatable neurological conditions. #Biotech #LifeScience #Neuroscience #Neurodevelopment

IAMA Therapeutics CEO Andrea P Malizia will be attending the #JefferiesHealthcare Conference November 14-16 in London, UK. #Biotech #LifeScience #Neuroscience #Neurodevelopment #Investment #Partnering #Dealmaking

This #NEAM2023, we honor the 3.4 million people living with epilepsy in the U.S. We are developing treatments to make a meaningful impact for children with CNS disorders like drug-resistant epilepsies. Learn more: bit.ly/3sawUFr #Epilepsy #Neuroscience #Neurodevelopment

November is National Family Caregivers Month in the U.S., a time to honor the dedication of family members who provide essential care and support to their loved ones affected by pediatric central nervous system disorders and more. #Biotech #Neuroscience #Epilepsy #Autism

IAMA Therapeutics is presenting new preclinical results supporting the potential for IAMA-6 as a disease-modifying therapy for drug-resistant epilepsies at the American Epilepsy Society #AES2023 Annual Meeting. Read more: bit.ly/3T8yYbU #Biotech #LifeScience #Neuroscience #Epilepsy

IAMA Therapeutics announced that the Italian Medicines Agency (AIFA) approved a Clinical Trial Application (CTA) to begin a Phase 1 Study of IAMA-6 for the treatment of #autism and #epilepsy. Read more: bit.ly/3TyvH5X #Biotech #Neuroscience #Neurodevelopment

IAMA Therapeutics is excited to be onsite at the 42nd Annual @JPMorgan Healthcare Conference in San Francisco this week. #JPM2024 #Biotech #Neuroscience #Epilepsy #Autism #Neurodevelopment #Investment #Partnering #Dealmaking

Exciting News! We've initiated our First-in-Human Clinical Trial for the treatment of neurodevelopmental disorders with IAMA-6. We’ve successfully dosed the first two cohorts, and we’re moving forward to the third. #IAMAtherapeutics #Neurodevelopment #ClinicalTrial #Biotech